Highlights Agenus Inc.

Equities

AGEN

US00847G8042

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
16.6 ^USD	+0.24%		+5.80%	+0.25%

May. 16	Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer	CI
May. 07	Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer	May. 16	CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	May. 07	MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07	MT
Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M	May. 07	MT
Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Ligand and Agenus Enter into $100 Million Royalty Financing Agreement to Support Agenus? Key Development Initiatives in the Ongoing Bot/Bal Clinical Development Program	May. 07	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	Apr. 12	MT
Sector Update: Health Care	Apr. 12	MT
Agenus Shares Decline After Update on Early Stage Colorectal Cancer Drug Trial	Apr. 12	MT
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer	Apr. 12	CI
Reverse Split: 1 of 20	Apr. 11	FA
Agenus Stockholders Approve 1-for-20 Reverse Stock Split	Apr. 05	MT
Earnings Flash (AGEN) AGENUS Posts Q4 Revenue $83.8M	Mar. 14	MT
Agenus Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Agenus Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Agenus Inc. Announces Preclinical Data on BMS-986442 at AACR 2024	Mar. 06	CI
Ginkgo Bioworks, Agenus Unit Win Contract to Discover, Develop Vaccine Adjuvants	Feb. 15	MT
Agenus Inc. Announces Data from an Investigator Sponsored Trial Evaluating Botensilimab in Combination with Balstilimab in Neoadjuvant Colorectal Cancer	Dec. 20	CI
Earnings Flash (AGEN) AGENUS Posts Q3 Revenue $24.3M	Nov. 07	MT
Agenus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Agenus Inc.

Equities

AGEN

US00847G8042

Highlights

Filters